Evidence map›Paper›PMID 32077136›Full record

ArticleBritish journal of clinical pharmacology2020

Precision therapy of 6-mercaptopurine in Chinese children with acute lymphoblastic leukaemia.

Yue Zhou, Li Wang, Xiao-Ying Zhai, Li Wen, Fang Tang, Fan Yang, Xi-Ting Liu, Lei Dong, Li-Juan Zhi, Hai-Yan Shi and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in British journal of clinical pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Association ofHaematologica · 2024
    Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Importance ofJournal of personalized medicine · 2021
    Review
  9. Article
  10. Article
  11. In vivo (Athens, Greece)
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 4 countries.

Yue ZhouDepartment of Clinical Pharmacy, School of Pharmaceutical Sciences, Shandong University, Jinan, China.
Li WangDepartment of Paediatric Haematology-Oncology, Children's Hospital of Hebei Province affiliated to Hebei Medical University, Shijiazhuang, China.
Xiao-Ying ZhaiDepartment of Paediatric Haematology-Oncology, Children's Hospital of Hebei Province affiliated to Hebei Medical University, Shijiazhuang, China.
Li WenDepartment of Paediatric Haematology-Oncology, Children's Hospital of Hebei Province affiliated to Hebei Medical University, Shijiazhuang, China.
Fang TangBig data Center, Shandong Provincial Qianfoshan Hospital, the First Hospital Affiliated with Shandong First Medical University, Jinan, China.
Fan YangDepartment of Clinical Pharmacy, School of Pharmaceutical Sciences, Shandong University, Jinan, China.
Xi-Ting LiuDepartment of Clinical Pharmacy, School of Pharmaceutical Sciences, Shandong University, Jinan, China.
Lei DongDepartment of Pharmacy, Children's Hospital of Hebei Province affiliated to Hebei Medical University, Shijiazhuang, China.
Li-Juan ZhiDepartment of Paediatric Haematology-Oncology, Children's Hospital of Hebei Province affiliated to Hebei Medical University, Shijiazhuang, China.
Hai-Yan ShiDepartment of Pharmacy, Shandong Provincial Qianfoshan Hospital, the First Hospital Affiliated with Shandong First Medical University, Jinan, China.
Guo-Xiang HaoDepartment of Clinical Pharmacy, School of Pharmaceutical Sciences, Shandong University, Jinan, China.
Yi ZhengDepartment of Clinical Pharmacy, School of Pharmaceutical Sciences, Shandong University, Jinan, China.
Evelyne Jacqz-AigrainUniversity Paris Diderot, Sorbonne Paris Cité, Paris, France.
Tian-You WangBeijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China.
Wei ZhaoDepartment of Clinical Pharmacy, School of Pharmaceutical Sciences, Shandong University, Jinan, China.ORCID 0000-0002-1830-338X
Shandong University · CNHebei Medical University · CNShandong Provincial QianFoShan Hospital · CNCapital Medical University · CNDélégation Paris 7 · FR

Funding

National Science and Technology Major Projects for "Major New Drugs Innovation and Development" 2017ZX09304029-001National Science and Technology Major Projects for "Major New Drugs Innovation and Development" 2017ZX09304029-002the Young Research Program of the Health Commission of Hebei Province 20180623Young Taishan Scholars Program of Shandong Province, Qilu Young Scholars Program of Shandong University
6 · The paper itself

Abstract

aimsChinese children are more susceptible to the development of thiopurine-induced leukopenia compared with Caucasian populations. The aim of our study was to establish a 6-mercaptopurine (6-MP) dose-concentration-response relationship through exploration of pharmacogenetic factors involved in the thiopurine-induced toxicities in Chinese paediatric patients afflicted by acute lymphoblastic leukaemia (ALL).

methodsBlood samples were obtained from ALL children treated with 6-MP. We determined the metabolite steady-state concentrations of 6-MP in red blood cells (RBCs) by using high-performance liquid chromatography. Pharmacogenetic analysis was carried out on patients' genomic DNA using the MassArray genotyping platform.

resultsSixty children afflicted by ALL who received 6-MP treatment were enrolled in this study. The median concentration of 6-thioguanine in patients afflicted by leukopenia was 235.83 pmol/8 × 10

conclusionOur findings support the idea that predetermination of genotypes and monitoring of thiopurine metabolism for Chinese paediatric patients afflicted by ALL is necessary to effectively predict the efficacy of treatments and to minimize the adverse effects of 6-MP maintenance therapy.

Indexed as

MercaptopurinePrecursor Cell Lymphoblastic Leukemia-LymphomaAntimetabolites, AntineoplasticChildChinaFemaleHumansMaleThioguanineAntimetabolites, AntineoplasticMercaptopurineThioguanineacute lymphoblastic leukaemiapaediatricpharmacogeneticsthiopurine metabolite levels

Identifiers

PMID32077136
PMCPMC7373713
OpenAlexW3008760290

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.